Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
出版年份 2018 全文链接
标题
Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways
作者
关键词
-
出版物
Scientific Reports
Volume 8, Issue 1, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-03
DOI
10.1038/s41598-018-30158-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
- (2016) Xiaoxin Wu et al. Anti-Cancer Agents in Medicinal Chemistry
- Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay
- (2016) Elodie Jouan et al. Pharmaceutics
- Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy
- (2015) Anna Barbuti et al. Cancers
- Targeting Microtubules by Natural Agents for Cancer Therapy
- (2014) E. Mukhtar et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
- (2012) Tongyuan Li et al. CELL
- Impairment of the Ubiquitin-Proteasome Pathway by MethylN-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells
- (2012) Nilambra Dogra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
- (2012) Yan Lu et al. PHARMACEUTICAL RESEARCH
- Metabolic regulation by p53
- (2011) Oliver D. K. Maddocks et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Free Tubulin Modulates Mitochondrial Membrane Potential in Cancer Cells
- (2010) E. N. Maldonado et al. CANCER RESEARCH
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function
- (2010) W. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
- (2009) C Stengel et al. BRITISH JOURNAL OF CANCER
- Proline Oxidase Functions as a Mitochondrial Tumor Suppressor in Human Cancers
- (2009) Y. Liu et al. CANCER RESEARCH
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- TTI-237: A Novel Microtubule-Active Compound with In vivo Antitumor Activity
- (2008) C. F. Beyer et al. CANCER RESEARCH
- Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53
- (2008) Julien Giustiniani et al. CELLULAR SIGNALLING
- Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
- (2008) Pascal Sève et al. LANCET ONCOLOGY
- Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells
- (2008) L. Shen et al. MOLECULAR CANCER THERAPEUTICS
- p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation
- (2008) Keiko Kawauchi et al. NATURE CELL BIOLOGY
- Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy
- (2008) Saroj P. Mathupala et al. SEMINARS IN CANCER BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation